Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 6/20 | 0.38 |
| ▸ | ACHE | P22303 | 6/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25063933 | 0.96 | MRGPRX4 (0.40) | FFAR1MRGPRX4BCHEACHENPC1 | |
| SCHEMBL25063926 | 0.92 | KDM4E (0.42) | FFAR1MRGPRX4BCHEACHENPC1 | |
| SCHEMBL24934758 | 0.88 | FFAR1 (0.41) | FFAR1MRGPRX4BCHEACHEPPARG | |
| SCHEMBL25063760 | 0.84 | MRGPRX4 (0.38) | FFAR1MRGPRX4BCHEACHENPC1 | |
| SCHEMBL25063754 | 0.84 | MRGPRX4 (0.40) | FFAR1MRGPRX4BCHEACHENPC1 | |
| SCHEMBL25063906 | 0.83 | FFAR1 (0.37) | FFAR1MRGPRX4BCHEACHENPC1 | |
| SCHEMBL25063899 | 0.83 | FFAR1 (0.37) | FFAR1MRGPRX4BCHEACHENPC1 | |
| SCHEMBL25063749 | 0.82 | MRGPRX4 (0.42) | FFAR1MRGPRX4BCHEACHENPC1 | |
| SCHEMBL24935382 | 0.82 | PPARG (0.45) | BCHEACHEPPARGNPC1GAA | |
| SCHEMBL21906794 | 0.81 | FFAR1 (0.41) | FFAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230054270-A1 | BIFUNCTIONAL COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| EP-4119546-A1 | BIFUNCTIONAL COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Suzhou Kintor Pharmaceuticals, Inc. (CN) | 2023-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054270-A1 | BIFUNCTIONAL COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | AR, SHBG, NR5A1 | FFAR1 620/4885MRGPRX4 3632/4885BCHE 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.